U.S. Markets closed

ChemoCentryx (CCXI) Looks Good: Stock Adds 5.5% in Session

Zacks Equity Research

ChemoCentryx, Inc. CCXI was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $10.01 –$11.24 in the past one-month time frame, witnessed a sharp increase yesterday.

The company has seen two positive estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for ChemoCentryx. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

ChemoCentryx currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.  

ChemoCentryx, Inc. Price

ChemoCentryx, Inc. Price | ChemoCentryx, Inc. Quote

Investors interested in the Medical - Drugs industry may consider AIT Therapeutics, Inc. AITB, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is CCXI going up? Or down? Predict to see what others think:Up or Down

Zacks' Top 10 Stocks for 2019
 
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
 
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
 
See Latest Stocks Today >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
ChemoCentryx, Inc. (CCXI) : Free Stock Analysis Report
 
AIT Therapeutics, Inc. (AITB) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research